Accéder au contenu
Merck

T7205

Tegafur

≥98% (HPLC), powder

Synonyme(s) :

5-Fluoro-1-(tetrahydro-2-furyl)uracil, Ftorafur, Tegafur

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement


A propos de cet article

Formule empirique (notation de Hill) :
C8H9FN2O3
Numéro CAS:
Poids moléculaire :
200.17
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
241-846-2
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

InChI key

WFWLQNSHRPWKFK-UHFFFAOYSA-N

InChI

1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)

SMILES string

FC1=CN(C2CCCO2)C(=O)NC1=O

assay

≥98% (HPLC)

form

powder

color

white to off-white

mp

171-173 °C (lit.)

solubility

DMSO: >50 mg/mL

storage temp.

room temp

Quality Level

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Application

Tegafur has been used as an internal standard for the analysis of 5′DFCR (5′deoxyfluorocytidine) and 5′DFUR (5′deoxyfluorouridine) using HPLC techniques. Tegafur has also been used as an internal standard for the chromatographic assay of azidothymidine (AZT).

Biochem/physiol Actions

Tegafur is a pro-drug of 5-fluorouracil, an antimetabolite used as an antineoplastic agent. It has been used as adjuvant chemotherapy for curatively resected colorectal cancer therapy.

Preparation Note

Tegafur is soluble in DMSO at a concentration that is greater than 50 mg/ml.

pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Li-Feng Liu et al.
Chinese medical journal, 125(11), 1931-1935 (2012-08-14)
The pharmacokinetics of zidovudine (AZT) are possibly influenced by weight, age, sex, liver and renal functions, severity of disease, and ethnicity. Currently, little information is available on the steady-state pharmacokinetics of AZT in Chinese HIV-infected patients. The current study aimed
Terence C Tang et al.
Neoplasia (New York, N.Y.), 12(3), 264-274 (2010-03-18)
Hepatocellular carcinoma (HCC) is an intrinsically chemotherapy refractory malignancy. Development of effective therapeutic regimens would be facilitated by improved preclinical HCC models. Currently, most models consist of subcutaneous human tumor transplants in immunodeficient mice; however, these do not reproduce the
Koji Oba
International journal of clinical oncology, 14(2), 85-89 (2009-04-25)
A consensus regarding standard adjuvant chemotherapy for curatively resected gastric cancer has not been obtained between Japan and the Western world. In order to evaluate the effect of a tegafur-based regimen (the most frequently used regimen in Japan) compared with
Muhammad Wasif Saif et al.
Expert opinion on investigational drugs, 18(3), 335-348 (2009-02-27)
S-1 is an oral fluoropyrimidine that is designed to improve the antitumor activity of 5-fluorouracil (5-FU) concomitantly with an intent to reduce its toxicity. S-1 consists of tegafur, a prodrug of 5-FU combined with two 5-FU biochemical modulators:5-chloro-2,4-dihydroxypyridine (gimeracil or
P M Hoff
Investigational new drugs, 18(4), 331-342 (2000-11-18)
Protracted intravenous regimens of fluorouracil (5-FU) may be superior and better tolerated than intravenous bolus dosing. An effective oral regimen would allow a protracted course of 5-FU without the need for central venous lines and the associated increase in complications.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique